Literature DB >> 17131494

Targeting intestinal microflora in inflammatory bowel disease.

Mario Guslandi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17131494      PMCID： PMC4087793          DOI： 10.3748/wjg.v12.i44.7225

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


× No keyword cloud information.
  9 in total

1.  Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease.

Authors:  Lynne V McFarland
Journal:  Am J Gastroenterol       Date:  2006-04       Impact factor: 10.864

2.  A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease.

Authors:  Athos Bousvaros; Stefano Guandalini; Robert N Baldassano; Christine Botelho; Jonathan Evans; George D Ferry; Barry Goldin; Lori Hartigan; Subra Kugathasan; Joseph Levy; Karen F Murray; Maria Oliva-Hemker; Joel R Rosh; Vasundhara Tolia; Anna Zholudev; Jon A Vanderhoof; Patricia L Hibberd
Journal:  Inflamm Bowel Dis       Date:  2005-09       Impact factor: 5.325

3.  Rifaximin for active ulcerative colitis.

Authors:  Mario Guslandi; Maria Chiara Petrone; Pier Alberto Testoni
Journal:  Inflamm Bowel Dis       Date:  2006-04       Impact factor: 5.325

Review 4.  Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease.

Authors:  Akira Andoh; Yoshihide Fujiyama
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

5.  Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.

Authors:  M A Zocco; L Zileri dal Verme; F Cremonini; A C Piscaglia; E C Nista; M Candelli; M Novi; D Rigante; I A Cazzato; V Ojetti; A Armuzzi; G Gasbarrini; A Gasbarrini
Journal:  Aliment Pharmacol Ther       Date:  2006-06-01       Impact factor: 8.171

6.  Saccharomyces boulardii in maintenance treatment of Crohn's disease.

Authors:  M Guslandi; G Mezzi; M Sorghi; P A Testoni
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

7.  Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

Authors:  C Prantera; H Lochs; M Campieri; M L Scribano; G C Sturniolo; F Castiglione; M Cottone
Journal:  Aliment Pharmacol Ther       Date:  2006-04-15       Impact factor: 8.171

8.  Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.

Authors:  C Prantera; M L Scribano; G Falasco; A Andreoli; C Luzi
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

9.  A pilot trial of Saccharomyces boulardii in ulcerative colitis.

Authors:  Mario Guslandi; Patrizia Giollo; Pier Alberto Testoni
Journal:  Eur J Gastroenterol Hepatol       Date:  2003-06       Impact factor: 2.566
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.